

To the Copenhagen Stock Exchange
Announcement No. 01-07 / 9 January 2007

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

TopoTarget Publishes Financial Calendar for 2007

Copenhagen, Denmark - 9 January 2007 – TopoTarget A/S (Copenhagen Stock Exchange: TOPO) expects to publish financial reports on the following dates over the next 12 months:

| | |
|--|-----------------|
| Annual report for 2006 | 14 March 2007 |
| Financial report for the first quarter of 2007 | 9 May 2007 |
| Financial report for the first half of 2007 | 15 August 2007 |
| Financial report for the third quarter of 2007 | 7 November 2007 |

The company's next Annual General Meeting is planned for 11 April 2007.

TopoTarget A/S

For further information, please contact:

| | | |
|-------------------------|-----------|------------------|
| Dr Peter Buhl Jensen | Telephone | +45 39 17 83 41 |
| Chief Executive Officer | Mobile | +45 21 60 89 22 |
| Tim Corcoran | Telephone | +44 1235 443 713 |
| Chief Operating Officer | Mobile | +44 787 656 1027 |

About TopoTarget

TopoTarget (OMX – The Nordic Exchange: TOPO) is a biopharmaceutical company, headquartered in Denmark and with subsidiaries in the UK, Germany and the USA, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer enzyme regulators (mainly HDAC, mTOR, and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule preclinical drug candidates and seven drugs are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™ is TopoTarget's first product on the market. In addition to organic growth, TopoTarget consistently looks for opportunities to strengthen and expand its activities through acquisitions and in-licensing. For more information, please refer to www.topotarget.com.

